Skip to main content
. 2011 Dec 20;11(12):968–974. doi: 10.5812/kowsar.1735143X.789

Table 4. Platelet Count (103/μL) in treated children.

Treated children, No. Baseline After 12 Wk After 24 Wk End of Treatment
IFN + RBV (n = 119)
SVR a 62 268 ± 66 b 221 ± 57 b 236 ± 66 261 ± 78
Treatment-naïve 53 267 ± 62 220 ± 57 235 ± 66 255 ± 79
Retherapy 9 273 ± 86 229 ± 61 243 ± 66 289 ± 71
NR a 57 269 ± 77 b 215±62 b 217 ± 61 b 258 ± 86
Treatment-naïve 48 272 ± 76 217 ± 61 221 ± 61 261 ± 90
Retherapy 9 254 ± 80 205 ± 66 203 ± 64 229 ± 50
Peg-IFN-α-2b + RBV (n = 51)
SVR 24 245 ± 65 b 172 ± 45 b 181 ± 55 215 ± 64
Treatment-naïve 15 244 ± 72 166 ± 46 171 ± 60 190 ± 50
Retherapy 9 246 ± 55 182 ± 45 196 ± 44 247 ± 69
NR 27 277 ± 70 b 198±45 b 204 ± 50 234 ± 45
Treatment-naïve 10 247 ± 48 182 ± 47 194 ± 49 215 ± 37
Retherapy 17 295 ± 77 208 ± 42 209 ± 51 244 ± 46

a Abbreviations: nR; non-responders, SVR; Sustained virological response

b Statistically significant difference, P < 0.05 (time dependent in one group)